Group B streptococcus serotype V

Greenberg, David N.; Ascher, David P.; Yoder, Bradley A.; Hensley, Donna; Heiman, Howard S.; Keith, Julian F.

doi:10.1016/s0022-3476(05)81778-0

Cited by 13 publications

(6 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Until recently, when there have been increasing reports of a changing spectrum of invasive GBS disease with the emergence of serotype V [8,[24][25][26] and other serotypes [27,28], there had been almost equal distributions reported of all GBS isolates in healthy adults, children, and neonates into 3 major serotypes: I, II, and III [29][30][31][32][33]. Infants with early-onset GBS infection without central nervous system involvement also experienced a similar distribution of serotypes.…”

Section: Discussionmentioning

confidence: 99%

Antibodies to Capsular Polysaccharides of Group BStreptococcusin Pregnant Canadian Women: Relationship to Colonization Status and Infection in the Neonate

et al. 2001

View full text Add to dashboard Cite

In a cohort study of 1207 pregnant women in Alberta, Canada, the serotype distributions of vaginal-rectal group B Streptococcus (GBS) isolates were compared with all isolates from neonates with invasive GBS disease identified by population-based surveillance. Serum concentrations of Ia, Ib, II, III, and V capsular polysaccharide (CPS)-specific IgG also were determined, according to serotype of the vaginal-rectal colonizing GBS strain. GBS colonization was detected in 19.5% (235 of 1207) of women. Serotype III accounted for 20.6% (48 of 233) of colonizing strains available for typing but for 37% (27 of 73) of invasive isolates from neonates (P<.01). Maternal colonization with type III was least likely to be associated with moderate concentrations of III CPS-specific IgG. Serotype III GBS is more invasive than other serotypes in this population; this may be due, at least in part, to poor maternal type III CPS-specific antibody response.

show abstract

Section: Discussionmentioning

confidence: 99%

Antibodies to Capsular Polysaccharides of Group BStreptococcusin Pregnant Canadian Women: Relationship to Colonization Status and Infection in the Neonate

et al. 2001

View full text Add to dashboard Cite

show abstract

“…The first reports of serotype V causing infection in neonates occurred in the early 1990s [8][9][10]. Wessels et al [11] subsequently purified the type V capsular polysaccharide (CPS) and verified that it was structurally unique from the other capsular types, as well as antigenically and immunologically distinct.…”

mentioning

confidence: 99%

Use of Type V Group B Streptococcal Conjugate Vaccine in Adults 65–85 Years Old

Palazzi¹,

Rench²,

Edwards³

et al. 2004

J INFECT DIS

View full text Add to dashboard Cite

For 130 years, group B Streptococcus (GBS) has been a frequent cause of neonatal mortality and pregnancyrelated morbidity. It also is an important cause of invasive infections in nonpregnant adults who have underlying medical conditions such as diabetes mellitus, chronic liver disease, renal insufficiency, and malignancy. Furthermore, age 164 years, in the absence of underlying disease, poses an increased risk for invasive GBS infection [1][2][3].Despite the success of maternal intrapartum chemoprophylaxis in reducing the incidence of neonatal early onset disease, over the course of the past 2 decades, there has been a 2-4-fold increase in GBS disease among nonpregnant adults, with rates of 4.1-7.2 cases/100,000 population [1,[5][6][7]. At present, more than two-thirds of invasive disease occurs in nonpregnant adults, with a mean age of 60 years and a case-fatality ratio approaching

show abstract

“…Four of the seven GBS serotypes identified thus far (Ta, Tb, TI, and III) are responsible for the majority of reported cases of infection in both neonates and adults in the United States (2,12). In addition to these four recognized major serotypes, recent reports of invasive infections caused by type V GBS suggest that this newly characterized serotype also may account for a significant fraction of neonatal infections now or in the future (15,17,28).…”

mentioning

confidence: 99%

Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine

et al. 1994

View full text Add to dashboard Cite

Most cases of neonatal sepsis and meningitis caused by group B streptococci (GBS) are attributable to one of four major capsular serotypes: Ia, Ib, II, or III. Because resistance to infection with GBS has been correlated with the presence of serum antibodies to the type-specific capsular polysaccharides in both experimental animals and human neonates, efforts have been made to elicit protective immunity with GBS capsular polysaccharide vaccines. However, the GBS capsular polysaccharides alone are not highly immunogenic in either animals or human volunteers. Therefore, we and other investigators have attempted to enhance immunogenicity by coupling individual capsular polysaccharides to a carrier protein. Here we report the synthesis and immunogenicity in rabbits of a GBS type Tb polysaccharide-tetanus toxoid vaccine prepared by the direct, covalent attachment of tetanus toxoid to a selected number of sialic acid residues on the type-specific polysaccharide. In addition, the Ib polysaccharide-tetanus toxoid conjugate vaccine was combined with similar tetanus toxoid conjugates of GBS type Ia, II, and III polysaccharides to form a tetravalent GBS conjugate vaccine. Protective efficacy of the GBS tetravalent conjugate vaccine was demonstrated in a mouse maternal immunization-neonatal challenge model of GBS infection. The results support testing in human subjects of a multivalent GBS conjugate vaccine of this design, with the eventual goal of protecting newborns against GBS infection.

show abstract

Group B streptococcus serotype V

Cited by 13 publications

References 2 publications

Antibodies to Capsular Polysaccharides of Group BStreptococcusin Pregnant Canadian Women: Relationship to Colonization Status and Infection in the Neonate

Antibodies to Capsular Polysaccharides of Group BStreptococcusin Pregnant Canadian Women: Relationship to Colonization Status and Infection in the Neonate

Use of Type V Group B Streptococcal Conjugate Vaccine in Adults 65–85 Years Old

Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine

Contact Info

Product

Resources

About